Table 2.
Pathological tumor features stratified for period of surgery.
| Pandemic Period (2020–2021) n = 4401 |
Post-Pandemic Period (2022–2023) n = 4785 |
p-Value | ||||
|---|---|---|---|---|---|---|
| 1117 | 1405 | 0.03 | ||||
| PROSTATECTOMY (n = 2522) |
pT stage, n. (%) | pT2 | 424 (37.9) | 542 (38.5) | 0.18 | |
| pT3a | 511 (45.7) | 602 (43.0) | ||||
| pT3b | 177 (16.0) | 254 (18.0) | ||||
| pT4 | 5 (0.4) | 7 (0.5) | ||||
| pN+, n. (%) | 159 (14.2) | 210 (14.9) | 0.24 | |||
| ISUP grade, median (IQR) | 3 (2–4) | 3 (2–4) | 0.33 | |||
| 1861 | 1890 | 0.21 | ||||
| TURBT (n = 3751) |
pT stage, n. (%) | pTis | 53 (2.8) | 58 (3.1) | 0.14 | |
| pTa | 786 (42.2) | 776 (41.1) | ||||
| pT1 | 893 (47.9) | 871 (46.0) | ||||
| pT2 | 129 (7.1) | 185 (9.8) | ||||
| Tumor grade, n. (%) | Low | 998 (53.6) | 1022 (54.0) | 0.38 | ||
| High | 863 (46,4) | 868 (46.0) | ||||
| Concomitant CIS, n. (%) | 241 (12.9) | 205 (10.8) | 0.29 | |||
| 252 | 246 | 0.18 | ||||
| CISTECTOMY (n = 508) |
pT stage, n. (%) | pT2 | 105 (41.6) | 111 (45.1) | 0.41 | |
| pT3a | 95 (37.6) | 89 (36.1) | ||||
| pT3b | 45 (18.1) | 37 (15.2) | ||||
| pT4 | 7 (2.7) | 9 (3.6) | ||||
| pN+, n. (%) | 41 (16.2) | 38 (15.4) | 0.38 | |||
| Histology variant, n. (%) | 32 (12.6) | 32 (13.0) | 0.28 | |||
| 170 | 185 | 0.34 | ||||
| NEPHROURETERECTOMY (n = 355) |
pT stage, n. (%) | pT1 | 43 (25.2) | 39 (21.0) | 0.17 | |
| pT2 | 96 (56.4) | 109 (58.9) | ||||
| pT3 | 29 (17.0) | 33 (18.0) | ||||
| pT4 | 2 (1.4) | 4 (2.1) | ||||
| pN+, n. (%) | 25 (14.7) | 31 (16.7) | 0.24 | |||
| Lymphovascular invasion, n. (%) | 53 (25.2) | 46 (24.8) | 0.28 | |||
| Histology variant, n. (%) | 19 (11.1) | 17 (9.1) | 0.45 | |||
| 190 | 201 | 0.24 | ||||
| RADICAL NEPHRECTOMY (n = 391) |
pT stage, n. (%) | pT1b | 24 (12.6) | 27 (13.4) | 0.19 | |
| pT2 | 69 (36.3) | 70 (34.8) | ||||
| pT3a | 81 (42.6) | 89 (44.2) | ||||
| pT3b/c | 10 (5.2) | 13 (6.4) | ||||
| pT4 | 6 (3.3) | 2 (1.2) | ||||
| pN+, n. (%) | 40 (21.0) | 38 (18.9) | 0.31 | |||
| Nuclear grade, median (IQR) | 3 (3–4) | 3 (3–4) | ||||
| Necrosis, n. (%) | 64 (33.6) | 72 (35.8) | 0.22 | |||
| 609 | 759 | 0.02 | ||||
| PARTIAL NEPHRECTOMY (n = 1468) |
pT stage, n. (%) | pT1a | 339 (55.6) | 401 (52.8) | 0.44 | |
| pT1b | 158 (25.9) | 221 (29.1) | ||||
| pT2 | 28 (4.5) | 36 (4.8) | ||||
| pT3a | 84 (14.0) | 101 (13.3) | ||||
| Nuclear grade, median (IQR) | 2 (1–3) | 2 (1–3) | 0.19 | |||
| Necrosis, n. (%) | 93 (13.1) | 101 (13.3) | 0.56 | |||
| 86 | 89 | 0.33 | ||||
| ORCHIECTOMY (n = 175) |
Disease stage, n. (%) | Ia | 19 (22.0) | 17 (19.1) | 0.26 | |
| Ib | 18 (22.1) | 22 (24.7) | ||||
| Is | 20 (23.2) | 15 (16.8) | ||||
| II | 21 (23.4) | 26 (29.3) | ||||
| III | 8 (9.3) | 9 (10.1) | ||||
| Lymphovascular invasion, n. (%) | 15 (17.4) | 17 (19.1) | 0.19 | |||
| Non-seminomatous germ cell tumors, n. (%) | 39 (45.3) | 38 (42.6) | 0.22 | |||
| 16 | 10 | 0.28 | ||||
| PENECTOMY (n = 26) |
Disease stage, n. (%) | I | 4 (25.0) | 3 (30.0) | 0.37 | |
| IIa | 5 (31.2) | 4 (40.0) | ||||
| IIb | 3 (18.7) | 2 (20.0) | ||||
| IIIa | 3 (18.7) | 1 (10.0) | ||||
| IIIb | 1 (6.4) | 0 (0.0) | ||||
| IV | 0 | 0 (0.0) | ||||
| Histopathological grading, median, (IQR) | 2 (1–3) | 2 (1–3) | 0.22 | |||